SCHEMBL4170634

SCHEMBL4170634

CCC(=O)Oc1c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c2c1=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 8/20 0.74
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
KDM4E B2RXH2 3/20 0.71
POLB P06746 3/20 0.71
GAA P10253 3/20 0.71
RECQL P46063 3/20 0.71
HSD17B10 Q99714 3/20 0.71
MMP1 P03956 2/20 0.71
MAPT P10636 2/20 0.71
APEX1 P27695 2/20 0.71
BLM P54132 2/20 0.71
HTT P42858 1/20 0.71
SRC P12931 6/20 0.71
EPHX2 P34913 2/20 0.69
NOX4 Q9NPH5 2/20 0.61
USP2 O75604 2/20 0.61
TP53 P04637 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165291 0.91 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4156001 0.91 POLH (0.70) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4169970 0.89 POLH (0.73) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4170035 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4170652 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4159135 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4170099 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4172289 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4175309 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB
SCHEMBL4163382 0.88 POLH (0.71) POLHMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090130051-A1 Flavonoid Compounds and Uses Thereof HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2009-05-21 US claimed
US-5607921-A Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to maximize its release, and use thereof L'OREAL (FR) 1997-03-04 US claimed
WO-2003105806-A1 STABILIZED RETINOL FOR COSMETIC DERMATOLOGICAL, AND PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF SALVONA L.L.C. (US) 2003-12-24 WO disclosed
US-20030232091-A1 Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof SHEFER ADI (US) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232091-A1 Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof RBP4, RBP1, RARA POLH 3650/4885MEN1 4402/4885KMT2A 3495/4885
US-20090130051-A1 Flavonoid Compounds and Uses Thereof CAT, NQO1, GPX4 POLH 3392/4885MEN1 4830/4885KMT2A 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.